Download MendeleyDiscovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
Jones, K.L., Beaumont, D.M., Bernard, S.G., Bit, R.A., Campbell, S.P., Chung, C.W., Cutler, L., Demont, E.H., Dennis, K., Gordon, L., Gray, J.R., Haase, M.V., Lewis, A.J., McCleary, S., Mitchell, D.J., Moore, S.M., Parr, N., Robb, O.J., Smithers, N., Soden, P.E., Suckling, C.J., Taylor, S., Walker, A.L., Watson, R.J., Prinjha, R.K.(2021) J Med Chem 64: 12200-12227
- PubMed: 34387088
- DOI: https://doi.org/10.1021/acs.jmedchem.1c00855
- Primary Citation of Related Structures:
7O18 - PubMed Abstract:
The functions of the bromodomain and extra terminal (BET) family of proteins have been implicated in a wide range of diseases, particularly in the oncology and immuno-inflammatory areas, and several inhibitors are under investigation in the clinic. To mitigate the risk of attrition of these compounds due to structurally related toxicity findings, additional molecules from distinct chemical series were required. Here we describe the structure- and property-based optimization of the in vivo tool molecule I-BET151 toward I-BET282E, a molecule with properties suitable for progression into clinical studies.
Organizational Affiliation:
GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K.
